Last updated: October 20, 2026
Ocrevus, Roche’s ocrelizumab, is the leading anti-CD20 therapy for multiple sclerosis and one of the company’s largest pharmaceutical products. Global sales increased from approximately CHF 4.6 billion in 2020 to about CHF 7.2 billion in 2024, driven by new-patient starts, expansion in primary progressive multiple sclerosis, and continued conversion from older disease-modifying therapies. The main commercial risks are competition from Kesimpta and Briumvi, biosimilar entry after the U.S. biologic exclusivity period, and pricing pressure in major markets.
Roche has reduced near-term erosion risk by launching Ocrevus Zunovo, a subcutaneous formulation administered every six months. The formulation creates a separate product lifecycle and may delay conversion of existing patients to competing anti-CD20 therapies.
What is Ocrevus and how does Roche generate revenue from it?
Ocrevus is a humanized monoclonal antibody against CD20-positive B cells. The FDA approved it in March 2017 for:
- Relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis.
- Primary progressive multiple sclerosis.
Ocrevus is administered intravenously every six months. In September 2024, the FDA approved Ocrevus Zunovo, a fixed-dose subcutaneous formulation containing ocrelizumab and recombinant human hyaluronidase. The injection is administered by a health-care professional over approximately 10 minutes every six months.[1]
The commercial model has several advantages:
- The twice-yearly schedule supports persistence and reduces adherence risk.
- Infusion-center administration creates switching friction.
- Ocrevus has the broadest approved MS label among several anti-CD20 competitors because it includes primary progressive MS.
- The subcutaneous formulation provides a differentiated delivery option for patients and providers.
Roche sells Ocrevus through Genentech in the United States and Roche affiliates internationally. The product is generally reimbursed under medical-benefit systems when administered in a clinic, although the reimbursement pathway can differ for Ocrevus Zunovo.
How has Ocrevus revenue changed over time?
Roche’s reported Ocrevus sales have grown substantially since launch.
| Year |
Approximate Roche sales |
Commercial development |
| 2017 |
CHF 0.9 billion |
U.S. launch year |
| 2018 |
CHF 2.4 billion |
Rapid adoption in relapsing MS |
| 2019 |
CHF 3.7 billion |
Broader international uptake |
| 2020 |
CHF 4.6 billion |
Resilient demand despite infusion disruption |
| 2021 |
CHF 5.5 billion |
Continued new-patient starts |
| 2022 |
CHF 5.7 billion |
Growth moderated by a large installed base |
| 2023 |
CHF 6.4 billion |
Higher volume and market expansion |
| 2024 |
Approximately CHF 7.2 billion |
Continued growth and Ocrevus Zunovo launch |
The figures are rounded from Roche annual-report disclosures and reported currency growth rates.[2-5] Roche typically reports group sales in Swiss francs and discusses growth at constant exchange rates, so reported values can differ from underlying volume growth.
What is driving Ocrevus revenue growth?
The primary growth drivers are:
- Continued use as an early high-efficacy therapy in relapsing MS.
- Increasing diagnosis and treatment of primary progressive MS.
- Switching from injectable and oral disease-modifying therapies.
- Expansion in markets where anti-CD20 treatment has become a standard high-efficacy option.
- Persistence associated with twice-yearly dosing.
- Introduction of a less burdensome subcutaneous administration option.
Ocrevus is also less exposed to generic substitution than older oral MS medicines because it is a biologic administered in clinical settings.
What could slow the financial trajectory?
Growth is likely to decelerate as the treated population becomes more mature. The main pressures are:
- Competition from Kesimpta, which offers self-administered monthly subcutaneous dosing.
- Competition from Briumvi, another anti-CD20 antibody administered intravenously.
- Rebates and formulary restrictions in the United States.
- A shift toward earlier use of high-efficacy therapies that increases competitive bidding among anti-CD20 products.
- Biosimilar development after regulatory and patent barriers decline.
- Cannibalization of intravenous Ocrevus by Ocrevus Zunovo.
Ocrevus Zunovo may protect Roche’s franchise even if it reduces the revenue contribution of the intravenous product. Roche can preserve patients within its own franchise while offering providers an alternative to infusion-center administration.
When does Ocrevus lose regulatory exclusivity?
Ocrevus received FDA approval on March 28, 2017. As the reference product for a biologic license application, it received 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act. That period generally runs through March 2029.[6]
Regulatory exclusivity and patent protection are separate. A biosimilar applicant may develop and submit an application before the end of the 12-year period, but commercial launch remains subject to the statutory exclusivity period, patent disputes, settlement agreements, and any court-ordered injunction.
Ocrevus does not have the same five-year chemical-drug exclusivity framework that applies to small-molecule products under the Hatch-Waxman Act.
What is the Orange Book status of Ocrevus?
Ocrevus is not listed in the FDA Orange Book because it is a biologic, not a conventional small-molecule drug. The relevant FDA reference is the Purple Book, which identifies licensed biological products and biosimilar or interchangeable relationships.[7]
This distinction affects competition:
| Issue |
Small-molecule drug |
Ocrevus |
| Primary FDA reference |
Orange Book |
Purple Book |
| Competitive pathway |
ANDA |
351(k) biosimilar application |
| Patent challenge |
Paragraph IV certification |
BPCIA patent-exchange process |
| Automatic stay |
Up to 30 months in defined circumstances |
No identical Orange Book stay mechanism |
| Substitution |
Pharmacy substitution may apply |
Interchangeability designation is relevant |
Are there Paragraph IV challenges to Ocrevus?
No traditional Paragraph IV challenge applies to Ocrevus because Paragraph IV certifications are part of the Hatch-Waxman pathway for small-molecule drugs.
A biosimilar developer would use the BPCIA patent-disclosure and litigation process. The process can involve disclosure of the biosimilar application, exchange of patent information, infringement claims under 35 U.S.C. § 271(e)(2)(C), and commercial-launch notice.
As of the end of 2024, there was no FDA-approved ocrelizumab biosimilar and no publicly identified U.S. biosimilar launch. The absence of a Paragraph IV case does not mean that Ocrevus faces no patent challenge. The relevant risk would appear through BPCIA litigation, patent settlements, or a commercial launch agreement.
What patents protect Ocrevus?
Ocrevus is protected by a layered estate covering the antibody, therapeutic use, formulation, dosing, and delivery technology. Public patent records should be reviewed on a claim-by-claim basis because ownership, terminal disclaimers, patent-term adjustments, continuations, and jurisdiction-specific expiration dates can change the effective protection period.
The principal protection categories are:
Anti-CD20 antibody patents
These patents cover ocrelizumab or closely defined anti-CD20 antibody structures, sequences, binding properties, and uses. The earliest core patent protection is generally expected to expire around the end of the 2020s or early 2030s, subject to patent-term adjustment and extensions.
Method-of-use patents
Method patents can cover treatment of relapsing MS, primary progressive MS, dosing intervals, patient populations, or treatment sequencing. Their enforceability depends on claim scope and whether a biosimilar label includes the patented use.
Formulation and administration patents
The intravenous product may have patents covering concentration, excipients, stability, preparation, or infusion protocols. Ocrevus Zunovo creates an additional protection layer for subcutaneous delivery, including the combination of ocrelizumab with hyaluronidase and the administration method.
Delivery-platform rights
Ocrevus Zunovo uses Halozyme’s ENHANZE technology. Roche and Halozyme have entered into a global collaboration under which Roche obtained rights to use the technology for subcutaneous delivery of selected medicines, including Ocrevus-related development.[8] These rights can create additional contractual and patent barriers even when the underlying antibody patents approach expiration.
How strong is the Ocrevus patent estate?
The estate is commercially strong but not unlimited.
Strengths include:
- A biologic molecule with manufacturing complexity.
- Multiple patent categories rather than reliance on one composition patent.
- A broad FDA label.
- A newer subcutaneous formulation.
- Manufacturing know-how that is difficult to replicate from public information.
- Potentially different expiration dates across the United States, Europe, Japan, and other markets.
Weaknesses include:
- Core antibody patents eventually expire.
- Method-of-use patents can be narrower than composition claims.
- Biosimilars do not need to duplicate every commercial feature of Ocrevus.
- A biosimilar may initially launch with a restricted label if certain method claims remain enforceable.
- Patent validity challenges can target obviousness, written description, enablement, or claim construction.
What patent litigation affects Ocrevus?
There was no publicly identified major U.S. Ocrevus biosimilar litigation through the end of 2024. The competitive legal environment remains pre-launch rather than litigation-driven.
The most relevant future disputes would involve:
- Whether a biosimilar infringes antibody composition claims.
- Whether Roche’s patents validly cover the subcutaneous formulation.
- Whether a biosimilar can omit patented primary-progressive-MS or dosing indications.
- Whether Roche can obtain an injunction against a proposed launch.
- Whether a biosimilar developer reaches a confidential or public settlement with Roche.
A settlement could permit launch before the last asserted patent expires. The commercial date would depend on the settlement terms, patent validity, and the biosimilar’s label.
Which companies are challenging Ocrevus commercially?
Novartis Kesimpta
Kesimpta, or ofatumumab, is the closest commercial competitor in relapsing MS. It is self-administered subcutaneously and can appeal to patients who prefer home treatment rather than infusion-center visits.
Kesimpta’s advantages are convenience and self-administration. Ocrevus retains advantages in dosing frequency, physician control, established market share, and the primary progressive MS indication.
TG Therapeutics Briumvi
Briumvi, or ublituximab-xiiy, is an intravenous anti-CD20 therapy for relapsing forms of MS. Its positioning includes a relatively short infusion after the initial doses.
Briumvi competes directly for infusion-center capacity and high-efficacy treatment starts. Its smaller commercial base gives it room to grow, but Ocrevus has a substantial incumbent advantage.
Biogen Tysabri
Tysabri remains an important high-efficacy MS therapy. Its use is constrained by progressive multifocal leukoencephalopathy risk management and patient-selection considerations. Ocrevus has captured patients seeking an alternative high-efficacy therapy with twice-yearly administration.
Generic and low-cost therapies
Generic versions of older MS medicines, including teriflunomide and dimethyl fumarate, create price pressure at the lower-cost end of the market. They compete less directly with Ocrevus in high-efficacy treatment segments but can affect payer sequencing and treatment economics.
How does Ocrevus compare with Kesimpta and Briumvi?
| Product |
Company |
Target |
Administration |
Main approved MS segment |
Competitive position |
| Ocrevus |
Roche |
CD20 |
IV every six months; SC every six months with Zunovo |
Relapsing and primary progressive MS |
Incumbent, broad label |
| Kesimpta |
Novartis |
CD20 |
Monthly self-administered SC |
Relapsing MS |
Convenience and home use |
| Briumvi |
TG Therapeutics |
CD20 |
IV after initial dosing |
Relapsing MS |
Infusion competitor |
| Tysabri |
Biogen |
Alpha-4 integrin |
IV or SC at recurring intervals |
Relapsing MS |
High efficacy, safety-monitoring considerations |
Ocrevus has the broadest disease coverage in this group. Kesimpta has the strongest home-administration proposition. Briumvi competes on infusion time and price positioning.
What is the generic and biosimilar launch risk for Ocrevus?
The most likely initial U.S. biosimilar launch window is after March 2029, subject to patent settlements and court outcomes. Actual launch could occur later if Roche secures enforceable patents covering the molecule, formulation, or administration method.
A reasonable scenario framework is:
| Scenario |
Potential timing |
Commercial effect |
| Early negotiated biosimilar entry |
Around 2029-2030 |
Rapid payer-driven discounting |
| Delayed entry after patent litigation |
2030-2033 |
Gradual price erosion |
| Limited initial competition |
After 2033 |
Roche retains substantial pricing power |
| Subcutaneous-focused competition |
After relevant formulation patents |
Pressure concentrated on Ocrevus Zunovo |
Biosimilar erosion is unlikely to resemble automatic pharmacy substitution for a conventional tablet. Switching decisions will be influenced by neurologists, infusion providers, payers, contracting, immunogenicity data, and interchangeability status.
What licensing deals support the Ocrevus franchise?
Roche’s core ocrelizumab rights are internally controlled through Genentech and Roche. The most commercially relevant external technology relationship is the Halozyme ENHANZE collaboration supporting subcutaneous delivery.
The licensing structure matters because Ocrevus Zunovo relies on an external delivery platform. Roche must manage both product patents and contractual rights to the delivery technology. That arrangement can support lifecycle management but also creates royalty or supply obligations.
What is the geographic coverage of Ocrevus?
Ocrevus is approved in the United States, the European Union, Japan, and other major markets. Patent duration and biosimilar timing will differ by jurisdiction.
The United States is the largest commercial market and the most important source of future patent litigation. Europe may experience earlier price pressure because national reimbursement agencies negotiate prices and biosimilar uptake can be faster. Emerging markets may have weaker enforcement, lower net prices, and earlier local competition.
How much revenue is exposed to Ocrevus patent expiry?
Ocrevus represented roughly CHF 7 billion or more of annual revenue for Roche in 2024, making it one of the company’s largest patent-exposed products. The exposure is material but partly mitigated by:
- Ocrevus Zunovo conversion.
- Continued growth in treated MS prevalence.
- International expansion.
- Potential settlement-controlled biosimilar entry.
- Manufacturing complexity.
- Roche’s broader MS franchise and commercial infrastructure.
A 10% net-price reduction on CHF 7.2 billion of annual sales would imply approximately CHF 720 million of gross annual revenue pressure before volume effects, foreign-exchange changes, and patient growth. A 30% reduction would imply approximately CHF 2.2 billion of gross annual pressure. Actual erosion would depend on the number of competitors, payer mandates, and the pace of conversion to biosimilars.
Key Takeaways
- Ocrevus is Roche’s leading MS product and generated approximately CHF 7.2 billion in 2024 sales.
- FDA reference-product exclusivity generally runs through March 2029.
- Ocrevus is governed by the Purple Book and BPCIA, not the Orange Book and Paragraph IV process.
- No FDA-approved ocrelizumab biosimilar or major public U.S. biosimilar litigation was identified through the end of 2024.
- Kesimpta is the strongest commercial competitor in relapsing MS; Briumvi is the closest intravenous competitor.
- Ocrevus Zunovo is Roche’s principal lifecycle-management product and may preserve franchise revenue after biosimilar entry.
- The major long-term risks are anti-CD20 competition, biosimilar price erosion, payer pressure, and loss of exclusivity for core antibody claims.
- Manufacturing complexity and formulation, use, and delivery patents may delay but are unlikely to eliminate eventual biosimilar competition.
FAQs
Is Ocrevus a biologic or a small-molecule drug?
Ocrevus is a biologic monoclonal antibody. Its active ingredient is ocrelizumab, a humanized anti-CD20 antibody.
Will Ocrevus Zunovo replace intravenous Ocrevus?
Ocrevus Zunovo is intended to expand administration options rather than immediately replace intravenous Ocrevus. Adoption will depend on reimbursement, provider economics, patient preference, and supply.
Is Kesimpta more convenient than Ocrevus?
Kesimpta is more convenient for patients who prefer self-administration at home. Ocrevus requires administration by a health-care professional but is given only twice per year.
Can a biosimilar launch before 2029?
A biosimilar developer can pursue development and regulatory preparation before 2029, but commercial launch is constrained by the 12-year reference-product exclusivity period and any enforceable patents.
What is the largest strategic threat to Ocrevus?
The largest strategic threat is cumulative pressure from Kesimpta, Briumvi, and later ocrelizumab biosimilars. Kesimpta presents the most immediate threat to relapsing-MS patient starts because it combines the anti-CD20 mechanism with home administration.
References
- U.S. Food and Drug Administration. (2024). FDA approves Ocrevus Zunovo for multiple sclerosis. FDA.
- Roche. (2021). Annual report 2021. Roche Holding AG.
- Roche. (2022). Annual report 2022. Roche Holding AG.
- Roche. (2023). Annual report 2023. Roche Holding AG.
- Roche. (2024). Annual report 2024. Roche Holding AG.
- U.S. Food and Drug Administration. (2024). Reference product exclusivity for biological products. FDA.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
- Halozyme Therapeutics, Inc. (2021). Halozyme and Roche enter into global collaboration for ENHANZE drug-delivery technology. Halozyme Therapeutics.
